 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...6768697071727374757677...235236» |
- 5-fluorouracil / Generic mfg.
Clinical significance of CA125 in unresectable pancreatic cancer treated with first-line chemotherapy. (Available On Demand; Poster Board No. M12) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_602;
This multicenter retrospective study comprised PC patients who received FOLFIRINOX or gemcitabine plus nab-paclitaxel in first-line setting between Jan 2014 and Dec 2021... CA125 is considered a clinically useful marker in unresectable PC treated with first-line chemotherapy because CA125 above the ULN is a poor prognostic factor for OS and an increased CA125 can be an early predictor of progression in patients with peritoneal dissemination.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Analysis of plasma circulating tumor DNA in borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant modified FOLFIRINOX: Clinical relevance of DNA damage repair gene alterations. (Available On Demand; Poster Board No. M4) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_594;
P2
Detection of germline or somatic mutations of DDR genes from plasma ctDNA at baseline was associated with better survival outcomes of patients with borderline resectable PDAC treated with neoadjuvant mFOLFIRINOX. Detection of DDR gene alterations from plasma ctDNA may have a potential role as biomarker for prognosis in patients with borderline resectable PDAC treated with mFOLFIRINOX.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN. (Available On Demand; Poster Board No. L20) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_590;
This interim analysis identified potential biomarkers of the gut microbiota that may contribute to the prognosis and efficacy of chemotherapy in pts with unresectable PC and BTC. The results of this analysis will be validated in the primary analysis.
- BMS-813160 / BMS, GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Chinook Therap, Opdivo (nivolumab) / Ono Pharma, BMS
Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study. (Available On Demand; Poster Board No. L17) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_587;
P1/2
This combination appears safe and neoadjuvant use does not lead to delay in surgery. Clinical trial information: NCT03767582.
- Imfinzi (durvalumab) / AstraZeneca
A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC). (Available On Demand; Poster Board No. L12) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_582;
P1/2
Immuno-genomic analyses of correlative biospecimens is underway. Funding support AstraZeneca.
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Efficacy of sequential perioperative FOLFIRNOX plus gemcitabine nab-paclitaxel for resected pancreatic and periampullary cancers. (Available On Demand; Poster Board No. L11) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_581;
Sequential perioperative chemotherapy combined FFX plus Gem/NabP for resected PC is effective and potentially prolongs survival, compared to historical controls who received single regimen. >
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Prediction of early treatment failure of second-line nal-iri/5-FU/FA in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216). (Available On Demand; Poster Board No. L8) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_578;
P3
In contrast, surrogate markers for tumor burden did not correlate with treatment success. Clinical trial information: NCT03468335.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma. (Available On Demand; Poster Board No. L2) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_573;
P2
Larger randomized trial is needed to validate the impact of neoadjuvant chemotherapy for resectable pancreatic cancer and to find subgroup of pts who would get benefit most from the neoadjuvant treatment. Post hoc genomic analyses with paired pre-neoadjuvant treatment and surgical tissues are ongoing.
- 5-fluorouracil / Generic mfg.
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer. (Available On Demand; Poster Board No. K18) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_569;
Females showed significantly more benefit than males. Further research on the selection for patient who will get the benefit from the third-line therapy is necessary.
- Outcomes of FOLFIRINOX and gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1: A propensity score–matching analysis. (Available On Demand; Poster Board No. K14) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_565;
Further research on the selection for patient who will get the benefit from the third-line therapy is necessary. Real world data suggests that GN may be recommended in PC pts with RFI < 6 mo from the last administration of adj S-1.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Multicenter observational study of nanoliposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Final retrospective results. (Available On Demand; Poster Board No. K13) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_564;
NFF had appropriate efficacy and manageable toxicity profiles, consistent with our previous report. NFF could be a candidate for 2nd-or-later-line regimens in the real world.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Efficacy and safety of nanoliposomal irinotecan plus fluorouracil and folinic acid after irinotecan-based chemotherapy in patients with advanced pancreatic cancer: Results of the retrospective part of the NAPOLEON-2 study. (Available On Demand; Poster Board No. K12) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_563;
Therefore, NFF is a possible treatment option after irinotecan-based chemotherapy. Further studies with a sufficient number of patients and a prospective design are warranted to examine the efficacy of NFF after irinotecan-based chemotherapy.
- Does neoadjuvant treatment in resectable pancreatic cancer improve disease outcomes? Systematic review and metanalysis of randomized controlled trials. (Available On Demand; Poster Board No. K11) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_562;
Neoadjuvant treatment improves R0 rates in about 20%. Randomized ongoing trials are eagerly waited with more active combined regimens including modified FOLFIRINOX.
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
nITRO: A phase 2 study of perioperative liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) in patients with resectable pancreatic ductal adenocarcinoma (rPDAC). (Available On Demand; Poster Board No. K8) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_559;
P2
Perioperative NALIRIFOX allows to select those patients who may benefit from resection to the largest extent. Perioperative NALIRIFOX deserves further investigation in randomized trials comparing it with standard upfront surgery followed by adjuvant therapy.
- albumin-bound paclitaxel / Generic mfg.
Assessment of an emergency 14-day (d) integrative supportive care program (14-EISCP) followed by early chemotherapy (CTx) in symptomatic patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): A prospective ARCAD cohort study. (Available On Demand; Poster Board No. K7) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_558;
P=N/A
Pts starting CTx within 30d had improved OS. Clinical trial information: NCT02979483.
- Effect of neoadjuvant therapy pathway (NATP) for pancreatic cancer on overall patient outcomes. (Available On Demand; Poster Board No. K2) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_553;
Implementation of NATP for pancreatic cancer within a single healthcare system increased the percentage of PDAC patients who underwent surgical resection and improved patient retention rate. Our data lay the foundation for further analysis of long-term outcomes of NAT in these patients.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO). (Available On Demand; Poster Board No. J10) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_543;
The survival signals are encouraging in a prognostically unfavorable albeit select patient population (relative to PRODIGE 24). Dose adjustments to facilitate optimizing tolerability is key.
- 5-fluorouracil / Generic mfg.
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study. (Available On Demand; Poster Board No. J8) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_541;
Though PFS was higher in the group of patients treated with GEMOX, a higher percentage of patients initially treated with FOLFIRINOX or Gemcitabine – Nabpaclitaxel reached 2nd line chemotherapy after progression. Percentage G3/4 Neutropenia, G1/2 Neuropathy and use of GCSF were significantly higher in patients treated with FOLFIRINOX.
- 5-fluorouracil / Generic mfg.
Electronic patient-reported outcome measured in patients with pancreatic cancer receiving second-line chemotherapy: A multicenter prospective observational study. (Available On Demand; Poster Board No. J7) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_540;
Further study is needed so that these trends can be taken into account in the management of chemotherapy. Clinical trial information: UMIN000044245.
- Analysis of survival outcomes in patients with pancreatic cancer who underwent upfront surgery. (Available On Demand; Poster Board No. J4) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_537;
Further studies are necessary for validation. >c-index by bootstrap validation (resampling, 1500) = 0.7088; *Calculate the weight score after setting the smallest beta-Coefficient (0.350) as the base constant, and the final scores are rounded to the nearest integer.; N stage was assessed using AJCC 8th.; HR, hazard ratio; CI, coefficient index.
- Proteomic profiling of antibody-drug conjugate (ADC) biomarkers in pancreatic cancer. (Available On Demand; Poster Board No. H15) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_529;
There is currently no approved ADC for pancreatic cancer, but several ADC clinical trials are underway. Quantitative proteomics identified antibody targets as well as markers of resistance or response to payloads for a variety of approved and investigational ADC therapies, which could aid in patient stratification in ADC clinical trials.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC). (Available On Demand; Poster Board No. G15) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_510;
P2
Clinical trial information: NCT03837977. >
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Serum vitamin D3 levels and overall survival (OS) in patients (pts) with advanced biliary tract cancer (BTC): Analysis of the NIFTY trial cohort. (Available On Demand; Poster Board No. G6) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_501;
High vitamin D3 levels might be associated with poorer survival in female pts. Further larger studies are needed.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation. (Available On Demand; Poster Board No. F10) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_487;
All patients received gemcitabine plus cisplatin as the frontline therapy, and 53.2% had fluoropyrimidine plus oxaliplatin (FOLFOX) before ICIs... The PD-L1 expression might be a novel biomarker for ICIs in BTC patients with KRAS mutation but not in those with the wild type of KRAS.
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial. (Available On Demand; Poster Board No. F5) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_482;
P3
For ABC patients, the presence of DDR-related gene pathogenic mutations are present in around one third of patients. Despite presence of DDR-mutations having a negative prognostic impact, their predictive role is not confirmed either for first-line CisGem or second-line FOLFOX.
- Early tumor shrinkage as a predictor of survival in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407. (Available On Demand; Poster Board No. C17) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_437;
Herein, we evaluated whether ETS could be a prognostic predictor in patients treated with modified FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) or GnP (gemcitabine plus nab-paclitaxel) for locally advanced pancreatic cancer (LAPC), as an exploratory analysis of JCOG1407, a randomized phase II selection design trial comparing modified FOLFIRINOX and GnP for LAPC. We noted a trend toward increased survival in patients who achieved ETS, suggesting that ETS may be a prognostic predictor in patients with LAPC treated with modified FOLFIRINOX or GnP.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
An active trend of immunotherapy combination regimen as second-line therapy for advanced biliary tract cancer: A multicenter retrospective study. (Available On Demand; Poster Board No. B10) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_410;
Immunotherapy combination strategy beyond first-line systemic chemotherapy plays a positive role in advanced BTCs. Both TKIs plus ICIs and chemotherapy plus ICIs could be considered as candidates to second-line trails and turn into a competitive second-line treatment regimen for advanced BTCs in clinical practice.
- Baizean (tislelizumab) / BeiGene, Novartis, sirexatamab (DKN-01) / Leap Therap
Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish). (Available On Demand; Poster Board No. N19) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_363;
P2
Part C is an ongoing, global, randomized phase 2 open-label study evaluating DKN-01 in combination with tislelizumab + chemotherapy (CAPOX or mFOLFOX6) vs tislelizumab + chemotherapy in patients with advanced G/GEJ adenocarcinoma...ESMO Annual Meeting September 2022. Clinical trial information: NCT04363801.
- veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC). (Live Stream | Level 3, Ballroom) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_353;
P2
The addition of P to TNT was associated with a statistically significant improvement in 3yr OS, but not DFS. Correlative molecular analyses are ongoing.
- Vectibix (panitumumab) / Amgen, Takeda
Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. (Live Stream | Level 3, Ballroom) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_345;
P3
These results warrant further validation in additional cohorts. Clinical trial information: NCT02394834.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial. (Live Stream | Level 3, Ballroom) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_343;
P3
For asymptomatic synchronous unresectable CRLMs, Pre-PTR chemotherapy improved the PFS compared with upfront PTR. Clinical trial information: NCT01307878.
- Opdivo (nivolumab) / Ono Pharma, BMS
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. (Available On Demand) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_323;
P3
Clinical trial information: NCT02872116. >Safety, all treated pts, n (%)NIVO + chemo (n = 782)Chemo (n = 767)Any-grade TRAEs739 (95)682 (89)Grade 3/4473 (60)346 (45)Leading to discontinuation331 (42)198 (26)
- zolbetuximab (IMAB362) / Astellas
Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab. (Available On Demand; Poster Board No. L12) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_284;
P1, P2
Treatment with zolbetuximab is associated with tumor and peripheral biomarker changes related to its proposed mechanism of action. Clinical responses observed in pts treated with zolbetuximab and mFOLFOX6 are associated with correlative biomarkers of activity including rapid deep molecular responses (ctDNA).
- Tecentriq (atezolizumab) / Roche
Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma. (Available On Demand; Poster Board No. H3) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_221;
P2
This trial supports further research of atezolizumab for the treatment of patients with localized EC and GEJ in the perioperative setting. Clinical trial information: NCT03784326.
- Imfinzi (durvalumab) / AstraZeneca
Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005. (Available On Demand; Poster Board No. G20) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_219;
P1/2
Survival times and response rates exceeded those expected for the regimens used (2 year survivals with FLOT 68% and CROSS 67%) in this non-randomised multi-centre trial. Clinical trial information: NCT02735239.
- 5-fluorouracil / Generic mfg.
Retrospective analysis of drug intake affecting the intestinal microbiota and the therapeutic effects of chemotherapy on gastric cancer. (Available On Demand; Poster Board No. F20) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_202;
In this study, there were no significant differences in PFS and OS between patients administered with or without antibiotics, antacids, or probiotic supplementation. Future studies are expected to investigate the impacts of these medications on the treatment outcomes of ICIs+Chemo combination.
- Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma. (Available On Demand; Poster Board No. F14) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_196;
Background: Docetaxel and cisplatin, 5-FU (DCF) is a standard neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCC) based on the results of the JCOG1109 study...NeoFLOT therapy (oxaliplatin: 85 mg/m2, leucovorin: 200 mg/m2, 5-FU: 2600 mg/m2, docetaxel: 50 mg/m2, every 2 weeks) was administered for 4 courses... NeoFLOT therapy showed well-tolerated and comparable efficacy with DCF therapy.
- Trimodality therapy with carboplatin/paclitaxel (CP) or FOLFOX (FFX) for esophageal/esogastric junctional cancer (EC/EGJ): Expanded safety and efficacy data from PROTECT. (Available On Demand; Poster Board No. F11) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_193;
P2
We could not demonstrate a significant benefit of CP compared to FFX in terms of survival outcomes, but the study was not primarily designed to specifically address this issue. Clinical trial information: NCT02359968.
- Opdivo (nivolumab) / Ono Pharma, BMS
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up. (Available On Demand; Poster Board No. E14) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_177;
P3
These results further support NIVO + chemo as a 1L treatment option for Chinese pts. Clinical trial information: NCT02872116.
- zanidatamab (ZW25) / Jazz
Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). (Available On Demand; Poster Board No. E8) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_172;
P2, P3
This maturing data set demonstrates durable disease control with encouraging cORR, DOR, PFS and OS results. A global Ph 3 study (HERIZON-GEA-01; NCT05152147) evaluating zani in combination with physician’s choice of standard chemo with or without the PD-1 inhibitor, tislelizumab, for first-line treatment of advanced HER2+ mGEA is currently enrolling.
- Keytruda (pembrolizumab) / Merck (MSD)
Treatment selection and outcomes of locally advanced esophageal cancer in octo- and nonagenarians: Is a curative intent multimodal approach feasible? (Available On Demand; Poster Board No. D14) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_159;
Multimodal standard of care treatment, including surgical resection, of locally advanced esophageal cancer in octo/nonagenarians is feasible and safe in a subset of this high-risk population and associated with improved outcomes compared to other approaches. Age alone should not bias against curative-intent treatment in elderly patients with esophageal cancer.
- docetaxel / Generic mfg.
Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade. (Available On Demand; Poster Board No. D13) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_158;
Patients with EAC undergoing curative intent neoadjuvant therapy with two similar docetaxel-based regimens (DCF - Docetaxel/Cisplatin/5FU or FLOT - 5FU, Leucovorin, Oxaliplatin, and Docetaxel) followed by en-bloc resection were included... This retrospective review, the largest yet reported, demonstrates that these similar docetaxel-based neoadjuvant chemotherapy regimens are highly effective for patients with locally advanced esophageal adenocarcinoma.
- Opdivo (nivolumab) / Ono Pharma, BMS
Exploring real-world outcomes with nivolumab plus chemotherapy in patients with advanced gastroesophageal adenocarcinoma. (Available On Demand; Poster Board No. D6) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_151;
The study is ongoing. Subsequent analyses will capture a larger patient sample and longer follow-up, and describe PD L1 CPS-based subgroups.
- 5-fluorouracil / Generic mfg.
Real-world outcomes with front-line doublet versus triplet chemotherapy in advanced gastroesophageal adenocarcinoma. (Available On Demand; Poster Board No. C12) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_140;
When limiting analysis to modern chemotherapy regimens however this data does suggest that a survival benefit may exist with the use of FLOT when compared to FOFOX/CapeOX. This finding would need to be further evaluated in prospective trials incorporating immunotherapy and targeted therapy prior to widespread recommendation.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI. (Available On Demand; Poster Board No. C6) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_134;
A phase III French intergroup study demonstrated a longer time to treatment failure, improved toxicity profile, and no difference in median OS when using FOLFIRI, compared to epirubicin, cisplatin, and capecitabine (ECX)... FOLFIRI had comparable efficacy to other first-line regimens in patients with AGC.
- Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. (Available On Demand; Poster Board No. B14) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_121;
P3
Oncologic and operative outcomes were consistent with optimum modern benchmarks. These data strongly suggest non-inferiority and support equipoise in clinical decision making in modern practice.
- Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. (Available On Demand) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_115;
P3
Oncologic and operative outcomes were consistent with optimum modern benchmarks. These data strongly suggest non-inferiority and support equipoise in clinical decision making in modern practice.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
The most effective systemic regimen appears to be FOLFIRINOX 3/ (Twitter) - Dec 13, 2022
- || Avastin (bevacizumab) / Roche
Biomarker, P2 data, Journal: A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR). (Pubmed Central) - Dec 13, 2022
The addition of BV was unable to compensate for the poor PFS associated with a high pVEGF-Asi level, suggesting that pVEGF-Asi is unlikely to be a good predictive biomarker of the efficacy of mFOLFOX6/XELOX + BV therapy. The clinical significance of circulating ICAM-1, mutant RAS, and mutant FBXW7 levels should be studied further.